Angiotensin Peptides and SARS-CoV-2: Mechanistic Insights from Recent Evidence

Study Background and Research Question

The renin-angiotensin-aldosterone system (RAAS) is central to cardiovascular and renal regulation, with peptides such as Angiotensin II and Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe) mediating critical physiological effects. Since the emergence of COVID-19, there has been intense interest in the interactions between RAAS peptides and viral pathogenesis, especially given that SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) for host cell entry. However, new evidence suggests that additional cell surface receptors, such as AXL, may facilitate SARS-CoV-2 infection, particularly in tissues with low ACE2 expression. This study by Oliveira et al. (2025) [DOI:10.3390/ijms26136067] investigates whether endogenous angiotensin peptides modulate the binding affinity of the SARS-CoV-2 spike protein to its key receptors (ACE2, NRP1, and AXL), thus expanding our understanding of molecular cross-talk between cardiovascular regulatory peptides and viral entry pathways.

Key Innovation from the Reference Study

The central innovation of Oliveira et al. lies in demonstrating that naturally occurring angiotensin peptides, including Angiotensin III, enhance the interaction between the SARS-CoV-2 spike protein and host cell receptors—with a pronounced effect on spike–AXL binding. This mechanistic link provides a new perspective on how RAAS peptides might contribute to viral infectivity and tissue tropism, beyond their classical roles in blood pressure regulation and aldosterone secretion [source_type: paper][source_link: https://doi.org/10.3390/ijms26136067]. The study further distinguishes between the effects of specific peptide truncations and modifications, highlighting structure-activity relationships relevant for both cardiovascular and infectious disease research.

Methods and Experimental Design Insights

Oliveira et al. employed antibody-based binding assays to measure how various angiotensin peptides influence the affinity of the SARS-CoV-2 spike protein for its receptors. The experimental design included:

• Comparison of angiotensin I (1–10), angiotensin II (1–8), Angiotensin III (2–8), angiotensin IV (3–8), and truncated/modified analogs for their capacity to modulate spike–receptor binding.
• Quantitative analysis of spike binding to AXL, ACE2, and NRP1 in the presence of each peptide.
• Assessment of the structural determinants (e.g., N-terminal versus C-terminal truncation, tyrosine modifications) that enhance or diminish the peptides' modulatory effects.

This approach allowed the authors to systematically dissect which angiotensin peptide sequences and modifications most potently enhance spike–receptor interactions [source_type: paper][source_link: https://doi.org/10.3390/ijms26136067].

Core Findings and Why They Matter

Key findings from the study include:

• Spike–AXL Binding Enhancement: Angiotensin II increased spike–AXL binding two-fold, while N-terminally truncated peptides such as Angiotensin III (2–8) and angiotensin IV (3–8) produced even greater enhancement (up to 2.7-fold with angiotensin IV) [source_type: paper][source_link: https://doi.org/10.3390/ijms26136067].
• Receptor Specificity: Unlike the effect on AXL, neither angiotensin I nor the peptides tested significantly altered spike–ACE2 or spike–NRP1 binding, except for the strong effect of angiotensin IV on these receptors.
• Structure-Activity Relationships: C-terminal truncations had less impact, while specific N-terminal deletions and tyrosine modifications (including phosphorylation at tyrosine 4) amplified spike–AXL binding. This suggests that the Arg-Val-Tyr motif, shared by Angiotensin III, is critical for this effect.

These findings position Angiotensin III not only as a classical aldosterone secretion inducer and pressor activity mediator, but also as a modulator of viral spike–receptor interactions. The implication is that the balance of RAAS peptides in tissues could influence susceptibility to SARS-CoV-2 infection, particularly in organs where AXL is highly expressed.

Comparison with Existing Internal Articles

Several internal resources contextualize these results within the broader landscape of cardiovascular and RAAS research:

• "Angiotensin III (human, mouse): Mechanistic Leverage and Emerging Roles" discusses Angiotensin III as a high-purity RAAS peptide with validated pressor and aldosterone-stimulating actions. Notably, this article anticipated the exploration of Angiotensin III in viral pathogenesis models, aligning with the present study's extension into SARS-CoV-2 research.
• "Angiotensin III (human, mouse): Advanced Insights for RAAS Research" provides detailed analysis of Angiotensin III's receptor signaling and solubility properties, with a brief mention of its emerging relevance in COVID-19 pathogenesis. The new evidence from Oliveira et al. adds crucial mechanistic detail to these prior perspectives.
• Other articles, such as "Precision Tool for Cardio...", focus on Angiotensin III's classic cardiovascular roles, but do not address its impact on viral spike–receptor interactions.

Collectively, these resources complement the reference study by outlining both the established and newly discovered functions of Angiotensin III in research workflows.

Limitations and Transferability

While the study provides compelling evidence that angiotensin peptides can enhance spike–AXL binding in vitro, several limitations must be considered:

• Cellular and Organismal Context: The binding assays were performed using purified proteins and antibody-based detection, which may not fully recapitulate the complexity of in vivo receptor expression, peptide processing, or local concentration gradients.
• Functional Consequences: Although enhanced spike–receptor binding is a plausible marker of increased viral entry, the study did not directly measure infectious outcomes or downstream signaling events in cellular models [source_type: paper][source_link: https://doi.org/10.3390/ijms26136067].
• Peptide Modifications: The relevance of tyrosine phosphorylation or substitution in physiological conditions requires further validation.

Thus, while the findings offer a mechanistic hypothesis for RAAS involvement in SARS-CoV-2 susceptibility, further investigation in biological systems is warranted before clinical translation.

Why this cross-domain matters, maturity, and limitations

This study bridges cardiovascular peptide biology and antiviral research by revealing that peptides like Angiotensin III—long recognized as an AT1 and AT2 receptor ligand and cardiovascular research peptide—also act as enhancers of SARS-CoV-2 spike–AXL binding. This cross-domain insight is significant for researchers exploring how comorbid cardiovascular conditions or RAAS-targeting therapies might influence COVID-19 outcomes. However, the evidence remains preclinical and exploratory; clinical implications should be drawn cautiously and only with further validation [source_type: paper][source_link: https://doi.org/10.3390/ijms26136067].

Protocol Parameters

• binding assay | 1–10 μM peptide | in vitro spike–receptor binding studies | matches concentrations used for measurable spike–AXL binding enhancement | paper [https://doi.org/10.3390/ijms26136067]
• peptide solubility in water | ≥23.2 mg/mL | peptide preparation for aqueous assays | ensures sufficient stock concentration for in vitro protocols | product_spec [https://www.apexbt.com/angiotensin-iii-human-mouse.html]
• peptide solubility in DMSO | ≥93.1 mg/mL | protocols requiring organic solvents | enables high-concentration stock solutions for parallel assays | product_spec [https://www.apexbt.com/angiotensin-iii-human-mouse.html]
• storage condition | -20°C, desiccated | long-term peptide stability | preserves compound purity and activity for reproducible results | product_spec [https://www.apexbt.com/angiotensin-iii-human-mouse.html]

Research Support Resources

For researchers aiming to replicate or extend these findings, Angiotensin III (human, mouse) (SKU A1043) from APExBIO offers a high-purity, sequence-confirmed RAAS peptide suitable for both cardiovascular and spike–receptor binding assays. Its robust solubility in water, ethanol, and DMSO supports flexible experimental design, and its validated performance underpins advanced studies of receptor signaling and viral pathogenesis [product_spec][source_link: https://www.apexbt.com/angiotensin-iii-human-mouse.html].